Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis.

Abstract

PURPOSE To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol. METHODS Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process. RESULTS Six months after beginning the new therapy, it was well-tolerated and the patient's RA and scleritis were quiescent. CONCLUSIONS Certolizumab pegol may successfully treat RA-associated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.

DOI: 10.1097/ICO.0b013e318211400a
050100201220132014201520162017
Citations per Year

167 Citations

Semantic Scholar estimates that this publication has 167 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Tlucek2012CertolizumabPT, title={Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis.}, author={Paul S Tlucek and Donald U. Stone}, journal={Cornea}, year={2012}, volume={31 1}, pages={90-1} }